DK0723780T3 - 2-Phenyl-3-azoylbenzothiophener til sænkning af serumcalciumniveauer - Google Patents
2-Phenyl-3-azoylbenzothiophener til sænkning af serumcalciumniveauerInfo
- Publication number
- DK0723780T3 DK0723780T3 DK96300610T DK96300610T DK0723780T3 DK 0723780 T3 DK0723780 T3 DK 0723780T3 DK 96300610 T DK96300610 T DK 96300610T DK 96300610 T DK96300610 T DK 96300610T DK 0723780 T3 DK0723780 T3 DK 0723780T3
- Authority
- DK
- Denmark
- Prior art keywords
- phenyl
- calcium levels
- serum calcium
- azoylbenzothiophenes
- lowering serum
- Prior art date
Links
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title abstract 2
- 229910052791 calcium Inorganic materials 0.000 title abstract 2
- 239000011575 calcium Substances 0.000 title abstract 2
- 210000002966 serum Anatomy 0.000 title abstract 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- -1 hexamethylene imino Chemical group 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 abstract 1
- 229960004622 raloxifene Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- FCEHBMOGCRZNNI-UHFFFAOYSA-N thianaphthalene Natural products C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Liquid Crystal Substances (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pyrrole Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/380,881 US5512583A (en) | 1995-01-30 | 1995-01-30 | Methods of decreasing serum calcium levels |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0723780T3 true DK0723780T3 (da) | 2002-06-17 |
Family
ID=23502813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK96300610T DK0723780T3 (da) | 1995-01-30 | 1996-01-29 | 2-Phenyl-3-azoylbenzothiophener til sænkning af serumcalciumniveauer |
Country Status (19)
Country | Link |
---|---|
US (1) | US5512583A (de) |
EP (1) | EP0723780B1 (de) |
JP (1) | JPH10513184A (de) |
KR (1) | KR19980701731A (de) |
CN (1) | CN1086943C (de) |
AT (1) | ATE216232T1 (de) |
AU (1) | AU701262B2 (de) |
CA (1) | CA2211530A1 (de) |
CZ (1) | CZ286161B6 (de) |
DE (1) | DE69620661T2 (de) |
DK (1) | DK0723780T3 (de) |
ES (1) | ES2172633T3 (de) |
HU (1) | HUP9801335A3 (de) |
NO (1) | NO973470D0 (de) |
NZ (1) | NZ302546A (de) |
PT (1) | PT723780E (de) |
RU (1) | RU2176503C2 (de) |
UA (1) | UA43389C2 (de) |
WO (1) | WO1996023501A1 (de) |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
US5075321A (en) * | 1987-03-24 | 1991-12-24 | University Of Pennsylvania | Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes |
US5395842A (en) * | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
TW366342B (en) * | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
DE4320896A1 (de) * | 1993-06-24 | 1995-01-05 | Denecke Rainer Dr Med Vet | Präparat zur Therapie und Prophylaxe von Demenz-Erkrankungen |
US5478847A (en) * | 1994-03-02 | 1995-12-26 | Eli Lilly And Company | Methods of use for inhibiting bone loss and lowering serum cholesterol |
PL181304B1 (pl) * | 1994-07-22 | 2001-07-31 | Lilly Co Eli | Preparat farmaceutyczny do hamowania zmniejszania masy kosci PL PL PL PL PL PL PL PL PL PL |
-
1995
- 1995-01-30 US US08/380,881 patent/US5512583A/en not_active Expired - Fee Related
-
1996
- 1996-01-29 JP JP8523733A patent/JPH10513184A/ja not_active Withdrawn
- 1996-01-29 HU HU9801335A patent/HUP9801335A3/hu unknown
- 1996-01-29 WO PCT/US1996/001406 patent/WO1996023501A1/en not_active Application Discontinuation
- 1996-01-29 AT AT96300610T patent/ATE216232T1/de not_active IP Right Cessation
- 1996-01-29 RU RU97114794/14A patent/RU2176503C2/ru active
- 1996-01-29 NZ NZ302546A patent/NZ302546A/en unknown
- 1996-01-29 AU AU48622/96A patent/AU701262B2/en not_active Ceased
- 1996-01-29 EP EP96300610A patent/EP0723780B1/de not_active Expired - Lifetime
- 1996-01-29 UA UA97074027A patent/UA43389C2/uk unknown
- 1996-01-29 PT PT96300610T patent/PT723780E/pt unknown
- 1996-01-29 DE DE69620661T patent/DE69620661T2/de not_active Expired - Fee Related
- 1996-01-29 CZ CZ19972403A patent/CZ286161B6/cs not_active IP Right Cessation
- 1996-01-29 ES ES96300610T patent/ES2172633T3/es not_active Expired - Lifetime
- 1996-01-29 DK DK96300610T patent/DK0723780T3/da active
- 1996-01-29 CN CN96191671A patent/CN1086943C/zh not_active Expired - Fee Related
- 1996-01-29 CA CA002211530A patent/CA2211530A1/en not_active Abandoned
- 1996-01-29 KR KR1019970705127A patent/KR19980701731A/ko not_active Application Discontinuation
-
1997
- 1997-07-28 NO NO973470A patent/NO973470D0/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CZ240397A3 (cs) | 1998-01-14 |
NO973470L (no) | 1997-07-28 |
RU2176503C2 (ru) | 2001-12-10 |
KR19980701731A (ko) | 1998-06-25 |
CA2211530A1 (en) | 1996-08-08 |
MX9705697A (es) | 1997-10-31 |
NZ302546A (en) | 2000-06-23 |
AU701262B2 (en) | 1999-01-21 |
WO1996023501A1 (en) | 1996-08-08 |
CZ286161B6 (cs) | 2000-01-12 |
EP0723780B1 (de) | 2002-04-17 |
AU4862296A (en) | 1996-08-21 |
HUP9801335A2 (hu) | 1999-05-28 |
US5512583A (en) | 1996-04-30 |
DE69620661D1 (de) | 2002-05-23 |
ES2172633T3 (es) | 2002-10-01 |
DE69620661T2 (de) | 2002-11-14 |
JPH10513184A (ja) | 1998-12-15 |
HUP9801335A3 (en) | 2000-03-28 |
PT723780E (pt) | 2002-08-30 |
EP0723780A3 (de) | 1996-09-11 |
ATE216232T1 (de) | 2002-05-15 |
EP0723780A2 (de) | 1996-07-31 |
CN1086943C (zh) | 2002-07-03 |
UA43389C2 (uk) | 2001-12-17 |
CN1172432A (zh) | 1998-02-04 |
NO973470D0 (no) | 1997-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0652001T3 (da) | Fremgangsmåder til behandling af det perimenopausale syndrom | |
DE69332735D1 (de) | Verwendung von Benzothiophene zur Behandlung von Hypercholesterolämie | |
GB2398781B (en) | Kinase inhibitors | |
DE60317198D1 (de) | Proteinkinaseinhibitoren | |
DK0848004T3 (da) | Pyrrolidinderivater med inhiberende aktivitet mod phospholipase A2 | |
HK1067963A1 (en) | Alpha-(n-sulphonamido)acetamide derivatives as beta-amyloid inhibitors | |
NO963370L (no) | Nye mercaptoacetylamido-1,3,4,5-tetrahydrobenzo[cÅazepin-3-on-disulfidderivater som er anvendbare som inhibitorer av enkefalinase og ACE | |
DK0747393T3 (da) | Dobbeltvirkende inhibitorer indeholdende en thiazolobenzazepinstruktur | |
NO20022125L (no) | Pyrrolderivater som inhibitorer for fosfodiesterase VII | |
EA199800123A1 (ru) | Способ получения n-замещенных 3-гидроксипиразолов | |
AU571513B2 (en) | Halogenated protease inhibitors | |
DK0723780T3 (da) | 2-Phenyl-3-azoylbenzothiophener til sænkning af serumcalciumniveauer | |
NO954609L (no) | Niopecotiske syrederivater som antitrombiske forbindelser | |
UA26459C2 (uk) | Іhгібітор впливу амілоїдhих білків | |
DE58902320D1 (de) | Thienyl-piperazinone, ihre herstellung und verwendung. | |
EP0711554A4 (de) | Antidepressivum | |
BR9609141A (pt) | Estabilização de nitrila | |
ES8301906A1 (es) | Un procedimiento para la preparacion de un derivado de sul- fonamida | |
MX9708875A (es) | Utilizacion de derivados de pirrolidina en la preparacion de medicamentos destinados al tratamiento de alcoholismo. |